programs detect prohibited drug use with sweat, hair, oral fluid, and/ or urine testing (S-.6). Understanding the excretion ofMAMP and its metabolite amphetamine (AMP) in sweat is important for interpreting results of sweat and hair monitoring methods. The importance of hair testing derives from transfer of MAMP in sweat to hair (z).
Sweat testing is conducted using patches cleared for use by the Food and Drug Admini>.'tration, which are usually worn for 1 week (a, S). Patches provide a qualitative record of an individual's drug use over the period of observation. Sweat patches are a less invasive means of specimen collection than blood testing and circumvent the privacy issues of urine collection. Disadvdntages are the possibility of time-dependent drug loss from the patch by drug degradation on the patch or skin, reabsorption into the skin, and volatile losses through the covering membrane of the patch (W) . There also are reports of patch contamination by cocaine, heroin, or MAMP remaining on the skin before patch application (!1). Despite these limitations, sweat testing can be useful if appropriate wash procedures are used before application, and patch removal is properly timed. A number of investigators have reported clinical study results for opiates (,4, n, .1.3), cocaine ffi, g, 14-,li), MAMP (18.) , and 3k methylenedioxymethamphetamine (MDMA) (!9) .
There have been no well-controlled studies of the excretion of MAMP or AMP into sweat. In an early report, investigators administered S-( + }-dimethylamphetamine to 2 individuals and collected sweat after physical exertion {2Q). They reported that the parent drug and its metabolite MAMP appeared in sweat as early as 1.5 h. Using immunoassay and GC-MS, Fay eta!. Wl) analyzed weekly sweat patches from known MAMP users and individuals given MAMP. The study was designed to validate the analytical method and did not fully describe the individuals or their drug use histoty. Pichini ct a!. (!g ) administered a single oral dose of 100 mg MDMA, a congener of MAMP, to 9 indi~iduals and found that the parent drug appeared in sweat after 1.5 hand peaked at 24 h. The between-individual mass of MDMA varied from 3.2 to 1326 ngjpatch. The metabolite 3A-methylenedioxyamphetamine (MDA) was present in trace amounts in the sweat of 7 of 9 individuals.
In this comprehensive double-blind, placebo-controlled, multiple-dose study, we examined sweat collected from 8 individuals before, during, and after daily oral administration of 4 low (10 mg) and high (20 mg) doses of sustained-release MAMP administered within 7 days. Times of 1st detection, peak and duration of excretion, and expected mass/patch of MAMP and AMP in sweat were measured by GC.MS. Data were analyzed using the limit of quantification (LOQ) of 2.5 ngjpatch and the Substance Abuse and Mental Health Sen~ces Administration (SAMHSA) proposed guidelines for M.A.MP and AMP sweat testing {3). These proposed guidelines establL~h a eonfinnation cutoff of 25 ngjpatch for each compound, with an additional requirement forAMPto be present at or above the method"s limit of detection to report a positive MAMP result.
Materials and Methods
Go to: Four male (2 Hispanic, 2 non-Hispanic white; ages 26 -39 years; weight 61.5-106.5 kg) and 4 female (4 Ahican Americans, ages 34 -43 years; weight s6.6 -75 kg) volunteers provided informed consent and were financially compensated for their time and effort during participation in this investigation, which ·was approved by the National Institute on Drug Abuse Institutional Re\~ew Board. Before admission, individuals with a history of stimulant and opioid use underwent thorough medical (physical exam, electrocardiography, and blood and urine chemistries) and psychological evaluations. For the duration of the study (1o weeks), participants resided on the secure clinical research unit, under 24-h medical surveillance, to ensure safety and to prevent additional drug use. The participants were free to conduct normal activities, including exercise in the air-conditioned facility and basketball and volleyball outside in a walled courtyard. The study was conducted over multiple years at all seasons of the year.
The 1st 2 weeks of tbe study served as a washout period to permit elimination of previously self-administered drugs. In the 3rd week, participants (n = 8) received 4 daily sustained-release doses of 10 mg Oow) oralS-(+ )-methamphetamine HCI (d·methamphetamine l!Cl) within a 7-day period (see l':J.g.i). ·n,e study design included 4 consecutive daily doses; howe\•er, some administrations were not on consecutive days because of either increased baseline heart rate or research unit schedules, but all were within 7 days. After at least a 3-week intetval that included administration of placebo, 5 of 8 participants also received 4 daily 20 mg (high) oral doses. Two participants were disqualified for medical reasons and a 3rd for personal issues. Participants were administered a single capsule containing 1 or 2 Desoxyn Gradumet 10-mg sustained-release tablets (Abbott Laboratories) with lactose (Amend Drug & Chemical Co., Inc.) as the filler. This formulation was developed to sustain slow release of drug after oral administration. For placebo treatments, the capsule contained only lactose filler. Additional information about the participants and administered drug and simultaneously obtained plasma, oral fluid, and urine data may be found in previous publications ill -!13.) .
.EI!l...1
Methamphetamine administration schedule for 4 1o-mg Oow) and 4 20-mg (high) oral MAMPdoses
SWEAT COLLECTION
Weekly sweat patches PharmChek® (PharmChem Inc.) sweat patches were applied to participants upon admission, 1 on the back and 1 on the abdomen, and removed at the end of 1 week. Duplicate patches also were applied in the same manner every week for the duration of the protocol (10 weeks). The sweat patch device consists of an adhesive layer on a thin transparent film of surgical dressing and a rectangular, absorbent, cellulose pad (14 em•). The surgical dressing film allows oxygen, carbon dioxide, and water vapor to escape while the nonvolatile constituents in sweat are retained in t he absorbent pad. Patches applied and removed in the 1st 2: weeks before dosing were termed washout patches. Dosing patches were applied before the 1st dose and removed up to 7 days later. Weekly patches applied after the end of drug administration were defined as postdose patches. Data for duplicate patches were reported individually, and median values were determined using all data, not using mean data for the replicates. Five (o.6%) of the 786 sweat patches did not adhere throughout the wear period. Unacceptable data were obtained for 3 patches (0-4%) owing to the lack of addition of internal standard. Nineteen patches (24%) were not applied owing to clinical or administration issues, and 28 (3.6%) were removed because of skin irritation. The most regrettable was the loss of 48 short-term and 20 weekly patches between collection and analysis. Further detail (whether the loss occurred during short-or long-tenn storage on the research unit) is unavailable.
SHORT-TERM SWEAT PATCHES
Single patches were applied to monitor excretion throughout each day that drug was administered (Fig 2) . The patches after the 1st dose covered the time periods o-2 h, 2-4 h, 4-8 h, 8-23 h (15-h patch), and 23-24 b (baseline patcl! for the next day's dosing). On subsequent dosing days, short -term sweat patches covered the periods of o-9 h and 9-24 h (15-h patch).
fi!!..l

Short-term sweat patch application and removal schedule
The skin was thoroughly cleaned with an isopropyl alcohol prep wipe (70% vol/vol) before patch application. After removal, patches were placed into plastic specimen bags along with a clean index card with identification information, sealed, and stored at -20 •c until analysis.
REAGENTS AND MATERIALS
We purchased MAMP, AMP,l'v!AMP-d 11 , and AMP-d, 0 from Cerilliant; N,Q-bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% trimethylchloro~ilane (TMCS) andN-methyl·N·(tert-butyldimethylsilyl)trifluoroacetamide (MTBSTI'A) with 1% lert-butyldimethylchlorosilane (TBDMCS) from Pierce Chemical; and filtration columns (RFVo2F4P) and solid-phase extraction (SPE) columns (Clean Screen CSDAUo2o) from United Chemical Technologies.
GCIMS ANALYSIS
We analyzed sweat patches for MAMP and AMP by modification of a published SPE GC/MS procedure (!4, ;M). These modifications permitted simultaneous quantification of MAMP, AMP, opiates, cocaine, and metabolites in a single analysis . Briefly, we addl'<l calibrators and control solutions to drug-free patches and added deuterated internal standards directly to calibrator, control, and participants' sweat patches. Patches were folded and placed into 12-mL filtration columns fitted with stopcocks. A 4-m!. aliquot of 0.5 moi/L sodium acetate buffer (pH 4.0) was added, and the sweat patch remained immersed in this solution for 30 min at room temperature. We collected buffered eluates in disposable 16 by 100mm glass te~1 tubes. This ~1ep was repeated twice using 2 mi. buffer and 30-min immersion intervals. We applied the combined buffered extracts (8 mL) to SPE columns preconditioned with 1 mi. freshly prepared elution solvent; methylene chloride: 2·propanol:ammonium hydroxide (80:20:2, volfvo!fvol), methanol (1 mL), distilled water (3 mL), and 1.5 mL of 2.0 mol/L sodium acetate buffer (pH 4.0). The columns were washed with distilled water (3 mL), 0.2 mol/ L hydrochloric acid (1.5 mL), and methanol (3 mL) and dried for smin under full vacuum. Analytes of interest were eluted using 5 aliquots (1 mL) of elution solvent. We added 20 IlL MTBSTFA with 1% TBD MCS to each tube to reduce MAMP and AMP volatility (;.la) and evaporated the eluates to dryness under nitrogen. Extracts were reconstituted in acetonitrile and subjected to dual derivatization with MTBSTI'A with 1% TBDMCS and BSTFA with t% TMCS. Derivatives were analyzed in splitless mode on an Agilent 6890 gas chromatograph/ 5973 In each analytical run, we constructed 2 calibration curves for each analyte to establish extended calibration ranges. Low (2.5-50 ngipatch) and high (50-soo ngjpatch) calibration curves (n = 10) were constructed for MAMP and AMP, with coefficients of determination (R 2 ) ;:0.989. LOQs for MAMP and AMP were 2.5 ng/patch. We calculated estimates of imprecision using duplicate controls from 10 analytical runs (n = 20) according to Krouwer and Rabinowitz <.:1.5). For all runs, the pooled within-run component of imprecision, expressed as %CV, was< 124% for all control concentrations (3.75, 12.5, 125, and 375 ngjpatch). Between-run imprecision (%CV) for all analytes, at all concentrations, was <12.1% for methamphetamine and <1o.6% for amphetamine. Total imprecision of the method (%CV) was reported as <17.8% and <20.8% for MAMP and AMP, respectively. Recoveries were within 10.2% of target concentrations.
We collected 682 sweat patches from 8 participants throughout the t o-week study. No weekly patch (n = 38) collected during the washout period had detectable MAMP or AMP. After controlled administration of 40 and So mg sustained-release MAMP (410-or 20-mg doses within 1 week), parent drug was the primary analyte detected in sweat. With the exception of 6 short-term patches, AMP was also detected in all patches with MAMP values >25 ngjpatch. In addition, 10 patches (t.s%) contained AMP above the method LOQ without concurrent MAMP; 5 of these were weekly patches.
MAMP was the only analyte detected in any short-term patch (n = 32) worn at intervals (o -2,2-4,4-8,8-23 h) after the fiTh1low-dose admini~1ration c:rahl!u). 1\velve of these short-term patches (37.5%) had MAMP above the LOQ. Because of the absence of AMP, no patch met the SAMHSA criteria for a positive result. After the first 20-mg MAMP administration, 75% of short-term sweat patches (n = 16) were positive for MAMP above the assay LOQ and 25% satisfied SAMIISA requirements for a positive specioten. MAMP was 1~1 detected in short-term sweat patches applied just before dosing and removed 2 h later (o-2 h). AMP was detected in short-term patches only after the high dose (Iallliu).
~ ::~phetaminc and amphetamine re;ults for hourly (2, 4, and 15 b) patches worn during or after a ~ single low-dose (10 mg) or high-dose (20 mg) oral MAMP administration.
Results for 15-h patches worn at the end of each day of MAMP admini~1ration are presented in~. After 4low and high doses, respectively, 67.7% of patches (n ~ 31) and 92.9% of patches (n = 14) were above the LOQ for MAMP, vs 25.8% and 78.6% for AMP. Five of 3115-h patches after low MAMl' doses were positive by SAMHSA guidelines, vs 7 of 14 after high doses. AMP was only present without MAMP in 2 of 49 patches, and never at ;,;25 ng/patch to fulfill SAMHSA requirements for a positive AMP sweat test. compared to the high doses (62.5%). However, this was not stati!>1ically significant using x• analysis (P > o.os), potentially owing to the small number of patches or to the differences in MAMP sweat excretion in the individuals receiving the low and high doses. For the weeks after either the low or high dosing week, there were no positive sweat patches when applying SAMHSA criteria c::r.a.bk.3). The week after t he low-dose week (n = 13), 61.5% and 30.8% of patches were above the L0Q for MAMP and AMP, respectively. Both analytes were below t he L0Q for all weekly patches collected 2 and 3 weeks after low dose. Note that many of the missing data points were for weeks that followed a week when patches were negative at the LOQ. One would expect these patches to also be negative. Detection rates increased after the high doses. In the week after the high MAMP doses (n = 7), 100.0% (MAMP) and 71.4% (AMP) of patch~'S exceeded the LOQ. In the same individuals, when using a 2.5Jlg/L urinary cutoff (LOQ), Oyler et al. W) reported last detection times up to 169 h from the last MAMP dose. Our results show positive sweat patches during this time frame (after dose week 1). In addition, 1 weekly patch collected in week 2 after high dose contained MAMP(15.2 ng). There were no positive urine tests at this time. All other week 2 and week 3 post dose patches had no detectable drug. There were no positive sweat patches with the proposed federally mandated cutoffs. Of course it is not expected that drug test results will be identical between matrices due to different analytes and analytical cutoffs, different periods of time for collection-i.e., sweat patches accumulate drug over 1 week vs a single urine sample representing only a few hours of excretion ~). Iah.l!:.A compares the cumulative massjpatch of MAMP and AMP in short-term patches to comparable weekly patches. For 9 of 12 dosing occasions, the cumulative mass/patch was greater than the average weekly mass/patch ofMAMP. Some differences were large, with cumulative mass/patch more than twice that of the average weekly patches. Differences for AMP between cumulative short-term and weekly patches were less frequent and of smaller magnitude.
~
Comparison ofMAMP and AMP mass per patch in dupHcate weekly sweat patches with corresponding cumulative mass per patch in hourly patches covering the same MAMP administration period.
Discussion
Go to:
This comprehensive, controlled, multiple oral dose MAMP administration study addressed the disposition of MAMP and its metabolite AMP in human sweat. The study "-as conducted on a closed research unit, and included a 2·week washout period to ensure that drug detected was not from prior self-administration. Sweat patches (n = 682) were applied and removed at various times to monitor excretion of drug into sweat during hourly and weekly timeframes. MAMP was the principal analyte identified after MAMP administration. This also was reported by Fay et aL ( . This group found that deuterated cocaine placed on sweat patches could be absorbed through skin over a period of time. TI1ey also observed up to 8-fold differences in mass cocaine/patch with patch location. We did not observe these differences for MAMP on sweat patches placed on the back and abdomen. I.Qss from patches did not appear to be significant for AMP.
Mass MAMP /sweat patch values were higher on t he 2nd day of administration, but median mass/patch did not continue to increase on subsequent dosing days. This also was true for mass MAMP /sweat patch in the subset of patches worn the last 15 h of each dosing day. These sweat patches showed that the median mass MAMP /patch was greater for the higher doses, but the number of patches positive using an LOQ cutoff or SAMHSA criteria were not significantly different between doses.
AMP did not appear in measurable amounts in sweat the 1st day after a 10-mg dose ofMAMP, but was excreted within the first 2 h for 1 individual after the 20-mg dose. Vree et al. (Jm) found that the metaboliteS-(+ )-methylamphetamine, after a 20-mg oral dose of S( + )-dimethylamphetamine, peaked in 5 and 7 h for 2 participants. One might expect in our study to see the highest mass/patch of the metabolite AMP in this time-frame. AMP also was present in 3 of 4 patches collected the last 15 h of the 1st high-dose day and in amounts that were about 10% of those for MAMP. On days 2 through 4 of the high-dose administration, AMP was detectable in most short-term patches, but was <25 ngfpatch.
It is interesting that a larger percentage of weekly sweat patches worn during low drug administration had MAMP above the LOQ for the low ( 92.9%) vs the high (62.5%) dose, despite the median mass MAMP / patch being >4 times higher. Using SAMHSA criteria yielded similar positive rates, 85.7% vs 62.5%. The differences are large but not statistically significant given the small sample size (x 2 , P > o.os). These results indicate that, "~th the recommended cutoff mass/patch, detection rates may vary independent of administered dose.
Our findings have implications for interpreting hair test results. Contamination of hair by drugs in sweat is well documented {2, ~-33), and hairtesting laboratories have different met hods for removing external contamination (29, 34, 35 ). Our results demonstrate that MAMP may be present in sweat within 2 h of oral ingestion and may be excreted for> 1 week after cessation of multiple uses. It is possible for MAMP in sweat to become incorporated into hair during this period of time.
Based on our results, clinicians who wish to monitor individuals in drug treatment programs can expect to detect a cumulative dose of MAMP as small as 40 mg with a weekly sweat patch. For indi~iduals taking a total dose of 80 mg MAMP, one would expect weekly patches worn during administration to be positive but patches applied in the weeks after drug cessation to be negative using SAMHSA criteria. These data provide a scientific database for interpreting MAMP and AMP sweat test results and contnoute to improved clinical monitoring of MAMP use. nw opinions in this article are those of the authors and do not necessarily reflect the views of\'he National Institute on Drug Abu.se or the Department of Defense
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